Faron Pharmaceuticals Oy (FRA:4FR) 3-Month Share Buyback Ratio: 0.00% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
33 GF Score
Price €0.45
! 5 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy 3-Month Share Buyback Ratio?

Faron Pharmaceuticals Oy FRA:4FR -0.98% 33 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates FRA:4FR with a GF Score™ of 33/100. The stock has 5 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:4FR
33GF Score
Faron Pharmaceuticals Oy FRA:4FR
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a 3-Month Share Buyback Ratio of 0.00 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's 3-Month Share Buyback Ratio too high?
Faron Pharmaceuticals Oy's current 3-Month Share Buyback Ratio is 0.00. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Faron Pharmaceuticals Oy's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current 3-Month Share Buyback Ratio of 0.00. The current 3-Month Share Buyback Ratio is 0.00. Faron Pharmaceuticals Oy's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
33GF Score

Get the complete analysis for FRA:4FR

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.45
Price